Olodaterol Hydrochloride Patent Expiration

Olodaterol Hydrochloride is Used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Striverdi Respimat on Jul 31, 2014.


Olodaterol Hydrochloride Patents

Given below is the list of patents protecting Olodaterol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Striverdi Respimat US8733341 Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct 16, 2030 Boehringer Ingelheim
Striverdi Respimat US7837235 Device for clamping a fluidic component Mar 13, 2028 Boehringer Ingelheim
Striverdi Respimat US9027967 Device for clamping a fluidic component Mar 31, 2027 Boehringer Ingelheim
Striverdi Respimat US7727984 Medicaments for the treatment of chronic obstructive pulmonary disease Jan 19, 2027 Boehringer Ingelheim
Striverdi Respimat US7396341 Blocking device for a locking stressing mechanism having a spring-actuated output drive device Oct 10, 2026 Boehringer Ingelheim
Striverdi Respimat US7896264 Microstructured high pressure nozzle with built-in filter function May 26, 2025 Boehringer Ingelheim
Striverdi Respimat US7220742 Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments May 12, 2025 Boehringer Ingelheim
Striverdi Respimat US8034809 Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments May 12, 2025 Boehringer Ingelheim
Striverdi Respimat US7284474 Piston-pumping system having o-ring seal properties Aug 26, 2024

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7056916 Medicaments for the treatment of chronic obstructive pulmonary disease Dec 07, 2023

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7491719 Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments Nov 10, 2023

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7786111 Medicaments for the treatment of chronic obstructive pulmonary disease Nov 10, 2023

(Expired)

Boehringer Ingelheim
Striverdi Respimat US8044046 Medicaments for the treatment of chronic obstructive pulmonary disease Nov 10, 2023

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7988001 Container provided with a pressure equalization opening Aug 04, 2021

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6988496 Cartridge for a liquid Feb 23, 2020

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7802568 Cartridge for a liquid Feb 26, 2019

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6846413 Microstructured filter Aug 28, 2018

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6977042 Microstructured filter Aug 28, 2018

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6149054 Mechanical counter for a metering apparatus Dec 19, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6453795 Locking mechanism for a spring-actuated device Dec 05, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US5964416 Device for producing high pressure in a fluid in miniature Oct 04, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6176442 Device for mounting a component exposed to a pressurized fluid Oct 04, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US6726124 Device for producing high pressure in a fluid in miniature Oct 04, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7104470 Device for producing high pressure in a fluid in miniature Oct 04, 2016

(Expired)

Boehringer Ingelheim
Striverdi Respimat US7246615 Atomising nozzle and filter and spray generating device May 31, 2016

(Expired)

Boehringer Ingelheim



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Olodaterol Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Olodaterol Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 19 Apr, 2023 US8044046
Payment of Maintenance Fee, 12th Year, Large Entity 03 Apr, 2023 US8034809
Payment of Maintenance Fee, 12th Year, Large Entity 23 Feb, 2022 US7786111
Payment of Maintenance Fee, 12th Year, Large Entity 24 Nov, 2021 US7727984
Payment of Maintenance Fee, 12th Year, Large Entity 11 Aug, 2020 US7491719
Patent Term Extension Certificate 16 Dec, 2019 US7727984
Payment of Maintenance Fee, 8th Year, Large Entity 16 Apr, 2019 US8044046
Payment of Maintenance Fee, 8th Year, Large Entity 02 Apr, 2019 US8034809
Notice of Final Determination -Eligible 02 Apr, 2019 US7727984
Payment of Maintenance Fee, 12th Year, Large Entity 14 Nov, 2018 US7220742


Olodaterol Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List